Dicot starts production of LIB-01 for human trials
Press release: Uppsala, March 4[th], 2021. The potency drug developer Dicot has started a new production of the drug candidate LIB-01. The batch will be used for the phase 1 human clinical trials starting in 2022.Dicot has just started a new production of the extract to be used for the drug candidate LIB-01. This is done in collaboration with Ardena in Södertälje, which is a certified CDMO (Contract Development & Manufacturing Organization). Ardena is an expert in managing the development and production of drug candidates and has, among other things, cutting-edge expertise in nano-medicine.